Abstract 51P
Background
Challenges persist in CAR-T cell therapy for solid tumors, notably due to immune exhaustion within the tumor microenvironment. Mesothelin (MSLN) has emerged as a pivotal target for CAR-T therapy in ovarian cancer, yet overcoming functional exhaustion remains a critical hurdle. This study explores the role of lipid metabolites in modulating anti-MSLN CAR-T cell exhaustion, aiming to enhance therapeutic outcomes.
Methods
Anti-MSLN CAR-T cells were engineered to target ovarian cancer cells with high MSLN expression for in vitro and in vivo experiments. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified oxylipin 12-HETE as critical in CAR-T cell exhaustion. High-throughput virtual screening (HTVS) identified an inhibitor targeting B7-H3.
Results
Our findings demonstrate that increased infiltration of T cells within mouse tumor models correlates with reduced tumor burden, attributed to 12-HETE-induced lipid peroxidation mediated via the GPR31 pathway. This process significantly impairs cancer cell viability and cytotoxic functionality of CAR-T cells. Mechanistically, we elucidate that interaction between the B7-H3 protein and HRAS in ovarian cancer cells inhibits FOXO3 regulatory activity, subsequently influencing 12-LOX expression critical in lipid metabolism regulation. Importantly, HTVS identified HI-TOPK-032 as an effective inhibitor that restores CAR-T cell infiltration and functionality, synergizing notably with anti-PD-1 blockade. Notably, HI-TOPK-032 amplifies the anticancer effects of CAR-T cells in patient-derived xenograft models of ovarian cancer characterized by elevated B7-H3 and 12-LOX expression.
Conclusions
This study underscores the pivotal role of lipid metabolism in CAR-T cell therapy efficacy against MSLN-expressing solid tumors. Our findings highlight the innovative strategy of targeting lipid pathways to mitigate immune exhaustion, presenting HI-TOPK-032 as a promising adjunct to enhance CAR-T cell therapy outcomes. These insights advance the understanding of immune modulation in ovarian cancer and propose a novel therapeutic approach poised for clinical translation.
Legal entity responsible for the study
The authors.
Funding
Capital Medical University Laboratory for Clinical Medicine and Gynecological Tumor Precise Diagnosis and Treatment Innovation Studio.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session